Equities Analysts Issue Forecasts for GLUE FY2024 Earnings

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Analysts at Lifesci Capital issued their FY2024 earnings estimates for Monte Rosa Therapeutics in a research report issued on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon anticipates that the company will post earnings per share of ($2.00) for the year. Lifesci Capital currently has a “Outperform” rating and a $19.00 target price on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share. Lifesci Capital also issued estimates for Monte Rosa Therapeutics’ Q4 2024 earnings at ($0.66) EPS.

Separately, Wells Fargo & Company downgraded shares of Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $14.00 to $11.00 in a research note on Thursday, December 19th.

Monte Rosa Therapeutics Trading Up 1.0 %

NASDAQ:GLUE opened at $6.27 on Friday. The company’s 50-day moving average price is $6.14 and its 200-day moving average price is $6.76. The company has a market cap of $385.21 million, a P/E ratio of -3.43 and a beta of 1.50. Monte Rosa Therapeutics has a twelve month low of $3.21 and a twelve month high of $12.40.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC increased its position in shares of Monte Rosa Therapeutics by 192.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company’s stock valued at $38,000 after acquiring an additional 3,584 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Monte Rosa Therapeutics by 10,665.5% during the fourth quarter. GAMMA Investing LLC now owns 5,921 shares of the company’s stock valued at $41,000 after acquiring an additional 5,866 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $43,000. Virtus ETF Advisers LLC acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $63,000. Finally, Focus Partners Wealth acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at about $77,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.